Two separate approaches to neutralising antibody production have recently yielded results for Ebolavirus – one from genetically-humanised mice and the other from a human survivor. The authors used these two models to generate antibodies against the SARS-CoV-2 spike protein, producing a large number of fully-human antibodies that they then characterised for binding, neutralisation and three dimensional structures. Using this, the authors selected pairs of highly-potent individual antibodies that could simultaneously bind the receptor-binding domain of the spike protein. These will be further developed as therapeutic antibody cocktails to decrease the potential for virus escape mutants that might arise in response to selective pressure from a single antibody treatment.
Read more here